Full history for every metric is available with a Kvantra account
LungLife AI, Inc. (LLAI.L)
Key financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -6 | 7 | |||||
| Net profit | $m | -3 | -5 | -6 | -7 | -8 | -5 | -4 |
| EPS reported | $ | -0.21 | -0.17 | |||||
| Operating cashflow per share | $ | -0.20 | -0.20 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -0.20 | -0.20 | |||||
| Free cash flow | $m | -5 | -4 | |||||
| Net debt | $m | -3 | -3 | |||||
| Book value equity | $m | 8 | 8 | |||||
| Book value per share | $ | 0.31 | 0.28 | |||||
| Number of shares | m | 25.49 | 28.37 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 1.89 | 0.21 | |||||
| P/S LTM | x | 324.44 | 58.08 | |||||
| P/FCF LTM | x | -2.93 | -0.39 | |||||
| EV/EBITDA LTM | x | -2.45 | 0.21 | |||||
| EV/Sales LTM | x | 272.74 | -32.23 | |||||
| Earnings Yield LTM | % | -36.27% | -386.38% | |||||
| FCF Yield | % | -34.15% | -257.74% | |||||
| Quality | ||||||||
| ROE | % | -68.41% | -51.42% | |||||
| ROIC | % | -67.78% | -67.78% | |||||
| Operating margin | % | -12243.5% | -12243.5% | |||||
| Gross margin | % | 100.00% | 100.00% | |||||
| FCF/Sales | % | -11080.4% | -11080.4% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +91.67% | -21.62% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -14.73 | -20.57 | |||||
| Net Debt/EBITDA | x | 0.47 | 0.47 | |||||
| EBIT/Net interest | x | -137.37 | -137.37 | |||||
| Net debt/market cap | % | -18.95% | -155.45% | |||||
| Net debt/Equity | x | -0.36 | -0.33 | |||||
| Gross debt/equity | x | 0.04 | 0.03 | |||||
Company overview
LungLife AI, Inc. is a clinical diagnostics enterprise focused on creating AI-powered solutions for detecting lung cancer. The company is actively developing LungLB, an advanced blood-based test that harnesses artificial intelligence and machine learning. LungLB is designed to precisely identify and quantify circulating tumor cells (CTCs), ultimately aiming to minimize manual intervention and elevate diagnostic performance. The organization, which was previously known as Cynvenio Biosystems, Inc., adopted the LungLife AI, Inc. moniker in May of 2019. Its operations are based in Thousand Oaks, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
LungLife AI, Inc. (LLAI.L)
LungLife AI, Inc. is a clinical diagnostics enterprise focused on creating AI-powered solutions for detecting lung cancer. The company is actively developing LungLB, an advanced blood-based test that harnesses artificial intelligence and machine learning. LungLB is designed to precisely identify and quantify circulating tumor cells (CTCs), ultimately aiming to minimize manual intervention and elevate diagnostic performance. The organization, which was previously known as Cynvenio Biosystems, Inc., adopted the LungLife AI, Inc. moniker in May of 2019. Its operations are based in Thousand Oaks, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free